In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
News|Podcasts|May 12, 2026
ACT Brief: Protocol Design as Business Strategy, Site Financial Pressures, and FDA Leadership Uncertainty
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine how protocol design decisions have become strategic business choices with outsized consequences for smaller companies, what clinical research sites need to compete and deliver, and leadership changes at the FDA.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In a new
Q&A , Mark Freitas, managing director and life sciences practice lead at A&M, discussed how clinical trial design has evolved into strategic business decisions. Analysis of 200 FDA CRLs revealed operational rather than scientific factors drive delays, with 57% of protocols receiving substantial amendments—nearly half avoidable. Small and midsize companies face bet-the-company choices in crowded therapeutic areas where evidence strategy and competitive positioning determine success. - In a new
FAQ article, clinical research sites are navigating financial instability, payment delays, feasibility misalignment, and technology burden. Approximately 80% of sites operate with six months or less of cash on hand, making timely transparent compensation essential to survival. Leading sites are using AI to accelerate feasibility and patient matching, turning data capabilities into competitive advantage while sponsors increasingly prioritize payment experience and realistic feasibility expectations. - President Trump is reportedly planning to
dismiss FDA Commissioner Marty Makary, according to sources, adding further leadership uncertainty across federal health agencies. Makary's tenure featured controversial positions including calls for large placebo-controlled vaccine trials in lower-risk cohorts and significant shifts in drug approvals, with concerns about political fallout influencing the decision.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
Trending on Applied Clinical Trials Online
1
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
2
FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine
3
Beyond the Molecule: Why Radiopharmaceutical Trials Require a New Operating Model
4
Operation TrialBlazer Leveraging New and Anticipated US Policy Changes in Early Development
5